NRx Pharmaceuticals (NASDAQ:NRXP) Announces Quarterly Earnings Results, Misses Estimates By $0.35 EPS

NRx Pharmaceuticals (NASDAQ:NRXP) announced its earnings results on Friday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.35), reports.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock traded down $0.07 during mid-day trading on Friday, hitting $3.27. The company’s stock had a trading volume of 1,124,669 shares, compared to its average volume of 1,198,563. The company’s fifty day simple moving average is $3.82 and its 200-day simple moving average is $2.95. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP increased its holdings in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares in the last quarter. State Street Corp boosted its holdings in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after buying an additional 10,700 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $994,000. Finally, Vanguard Group Inc. grew its position in shares of NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after buying an additional 82,781 shares during the period. Institutional investors and hedge funds own 4.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday. BTIG Research reduced their target price on NRx Pharmaceuticals to $10.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. Finally, Ascendiant Capital Markets boosted their price target on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.50.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.